OXFORD, UK, July 21st, 2016
PharmaVentures is pleased to announce that today it has launched a new FCA regulated firm, Pharmaventures Capital Ltd which will carry out all future FCA regulated corporate finance related mandates.
The new firm, which is 100% owned by PharmaVentures, will be able to expand our client offering to include: publice transactions; certain transactions involving listed companies; and fund raising.
Fintan Walton, Chief Executive of PharmaVentures said: “We are delighted to expand our offering to clients through this new FCA regulated firm as it is quite common for our clients to require a broader range of corporate finance advice”.
Those authorised to conduct regulated work include Fintan Walton, Chairman and Chief Executive, Stephen Waterman and Ping Shek, all of whom are Board Directors of PharmaVentures Capital Ltd. and Issac Jacob, Senior Director at PharmaVentures Ltd.
The Financial Conduct Authority is the major financial regulatory body in the UK which regulates the financial services industry in the UK. Its role includes protecting consumers, keeping the industry stable, and promoting healthy competition between financial service providers. The UK is one of the leading centres for financial services in the world.
For the past 24 years, PharmaVentures has acted as an advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activites for companies.